Promising results from Hepatitis E vaccine trial
An estimated 20 million hepatitis E virus (HEV) infections occur every year resulting to over 3 million acute cases of hepatitis E. A recent report published in the New England Journal of Medicine (March 2015) show hepatitis E vaccine induced...
12th Annual African Vaccinology Course
The Vaccines for Africa Initiative (VACFA) is pleased to announce the plans to conduct the 12th Annual African Vaccinology Course (AAVC) are at an advanced stage and applications will open soon. The 12th AAVC will be held between 7-11 November 2016...
WHO comments on the Ebola vaccines, therapies and diagnostics
The Ebola outbreak in West Africa has killed almost 10,000 people. Although the epidemic is finally slowing down, WHO warns there is still a lot to be done to contain further spread of the virus.


Friday, 24 March 2017

Measles is a highly contagious viral disease and one of the leading causes of death in children worldwide. Measles cases occur around the world. Within the last 10 years, the number of measles cases reported globally has decreased significantly; however, there have been a number of large outbreaks, mostly in Africa, Europe and the Americas.

Publication Date:
Tuesday, March 10, 2015 - 11:30

In an efficacy randomised controlled study with a follow up of up to 4.5 years, the investigators from the China study showed 87% of those who received three doses of the  hepatitis E vaccine maintained antibodies against HEV for at least 4.5 years.


Publication Date:
Thursday, March 5, 2015 - 15:30